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S(Heel wound, n¼28), and group E (Extensive wound extending onto the forefoot or
midfoot along with dorsum or plantar surfaces, n¼43). Successful revascularization
was deﬁned as achievement of direct blood ﬂow to the wounds evaluated by digital
subtraction angiography just after EVT.
Results: We achieved successful revascularization 73% in group T, 79% in group H,
and 51% in group E. In success group, wound healing rates were 81% in group T,
59% in group H, and 32% in group E (p < 0.001). On the other hand, in non-success
group, wound healing rates were 53% in group T, 33% in group H, and 0% in group E
(p < 0.001). Time to healing were 50 days (interquartile range: 23-99 days), and 65
days (28-156 days) in group T (p ¼ 0.20): 145 days (121-317 days), and 260 days
(234-285 days) in group H (p ¼ 0.39) with and without successful revascularization.
Conclusions: Successful revascularization increased wound healing rates of all types
wounds, however, time to healing was not statistically different with and without
successful revascularization. Not only successful revascularization but also various
factors are associated with wound healing in patients with CLI.
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Background: Inferior vena cava ﬁlters (IVCF) have increasingly been used for
prevention of pulmonary thromboembolism (PTE) in deep venous thrombosis (DVP)
when anticoagulant therapy is contraindicated or in patients presumed to be at high
risk. Persistent DVP and risk factors or lack of follow-up may account for IVCF left
permanently in place. We assessed long-term performance of permanent IVCF with
abdominal CT scan.
Methods: ALN IVCF (ALN Implants Chirurgicaux) is a retrievable, non-magnetic,
stainless steel ﬁlter consisting of nine legs. Six short legs (SL) provide anchorage and
three long legs (LL) allow coaxial ﬁlter positioning. Among 54 pts with DVP who
received ALN IVCF, 12 pts (58% female, mean age 55 years, range 19-80) with ﬁlter
left permanently in place underwent abdomen CT scan during follow-up. Six pts had
a second CT scan and one pt had four CT scans. Time from IVCF implantation to CT
scan follow-up ranged from 2 to 163 (mean 60) months. Penetration of ﬁlter into the
IVC wall was deﬁned as  3 mm protrusion of a leg outside the IVC wall. Grade 3
penetration was deﬁned as any interaction with an adjacent organ outside the IVC.
Fracture was deﬁned as any loss in structural integrity of the IVCF. Embolization was
deﬁned as remote endovascular migration of a fractured leg.
Results: In all pts (12/12), CT scan showed penetration of ﬁlter legs. Overall, 57/72
(79%) of the SL but only 1/32 (3%) of the LL were outside IVC wall. Grade 3
penetration of 13 (18%) SL was observed in 8(67%) pts: 9 into a vertebral body and 4
into small intestine. In 4 (33%) pts, 11 (15%) SL fractures were observed, while in 3
(25%) pts embolization of a total of 7 SL occurred: 3 in a pulmonary artery branch, 2
in the right side of the heart, 1 in the liver and 1 whose embolization site was not
found. None of the pts had clinical manifestations related to IVCF dysfunction.
Conclusions: IVC injury and loss of IVCF structural integrity seem to be the rule rather
than the exception after prolonged IVCF positioning. These ﬁndings should encourage
IVCF removal when possible. Furthermore, surveillance follow-up with abdominal
X-ray or CT scan in all patients with permanent IVCF is strongly advisable.
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Background: To compare clinical outcomes of endovascular intervention (EVI)
between octogenarians and non-octogenarians with peripheral arterial disease (PAD)
Methods: A retrospective analysis of 490 consecutive patients (619 legs) who
underwent EVI between June 2005 and February 2013, was conducted in a prospec-
tively maintained database. Patients  80 (128 patients, 158 limbs) and < 80 years old
(362 patients, 461 limbs) were compared to demographics, 30-day major adverse
vascular events (MACE), limb salvage, sustained clinical success (SCS), secondary
sustained clinical success (SSCS) and overall survival.
Results: Patients  80 were more likely to be female and have more atrial ﬁbrillation,
whereas those < 80 were more likely to have diabetes mellitus, dialysis dependence,
hyperlipidemia, high body mass index and claudicants. There were more multi-level
interventions in patients 80 (55%vs. 45%,p¼0.04). Theprocedure success rate (93.7%
vs. 94%, p¼1.0) and 30-day MACE were similar in both age groups (10.1% vs. 9.3%,
p¼1.0). The SCS (<80% vs.80, 56% vs. 53%, p¼0.859), SSCS (<80% vs.80, 72%
vs. 76%, p¼0.07) and limb salvage rates (<80% vs.80, 91% vs. 95%, p¼0.085) wereB158 JACC Vol 62/18/Suppl B j October 27–Nsimilar between both age groups at 24 months. Patients80 still have shorter survival as
compared to those <80 (57% vs. 71%, p<0.01) during the follow-up period.
Conclusions: Our results suggest EVI in octogenarian with more complex lesions is
safe and feasible without increasing the risk of complications. Although the overall
survival remained worse in this elderly group, 24-month SCS, SSCS and limb salvage
rate were similar in both age group. For patients 80 with PAD, EVI should be
considered as ﬁrst-line treatment of choice.
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Background: Although percutaneous transluminal renal artery stenting (PTRAS) has
become popular for treating atherosclerotic renal artery stenosis (ARAS), effect of
statin after PTRAS remains uncertain. The aim of this study is to examine the
inﬂuence of statin after PTRAS.
Methods: Consecutive 268 patients who were diagnosed as atherosclerotic renal
artery stenosis by duplex ultrasound and angiography received renal artery stenting,
and they were enrolled in the study between Aug 1996 and July 2010. Data were
collected on clinical outcomes over a mean follow-up period of 4330 months. The
primary endpoint was deﬁned as the composite of all-cause death, hospitalization of
heart failure, and initiation of dialysis.
Results: 89 patients (33%) received statin treatment during follow-up period.
According to Kaplan-Meier analysis, the log-rank test showed patients who received
statin treatment have a lower event rate than patients without statin (Log-rank test;
p¼0.03), and percentage with event was reduced by 10% in the patients with statin
treatment 5years after PTRAS.Conclusions: In conclusion, statin therapy was associated with a better outcome in
patients with atherosclerotic renal artery stenosis who were received PTRAS.
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Background: There are limited data regarding contemporary use and comparative
clinical outcomes of stent and non-stent based revascularization of infra-inguinal
peripheral arterial vessels.ovember 1, 2013 j TCT Abstracts/POSTER/Endovascular Intervention
www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM–5:30 PMMethods: We analyzed XLPAD registry data between July 2005-April 2013 to
compare atherectomyballoon angioplasty ('Non-stent') and stenting ('Stent')
outcomes for superﬁcial femoral artery (SFA), popliteal and below-the knee (BTK)
revascularization.
Results: A total of 413 interventions (SFA¼79.2%; popliteal¼9.2%; BTK¼11.5%)
were performed in 254 patients (Rutherford category 3¼81.7%; 4-5¼14.1%). Stents
were deployed in 60.8% of lesions (SFA¼ 92.4%; popliteal¼3.8%; BTK¼3.8%) and
non-stent strategy (atherectomy in 44.3%) used in 39.1% (SFA¼58.8%; pop-
liteal¼17.6%; BTK¼23.5%). In the 'Stent' and 'Non-stent' groups, mean lesion length
were 136.9 mm and 77.6 mm, respectively (p<0.001), with more interventions for
critical limb ischemia (CLI; p¼0.006) in the 'Non-stent' group. Chronic total
occlusions constituted 62.2% of 'Stent' and 38.0% of 'Non-stent' treated lesions
(p<0.001). At a median follow-up of 210 days (IQR¼120-330), all-cause mortality
was 5.3% in the 'Stent' and 4.6% in the 'Non-stent' treated patients (p¼0.79); repeat
revascularization (RR) was required in 19.0% 'Stent' and 17.8% 'Non-stent' patients
(p¼0.78) and amputation in 3.8% in 'Stent' and 9.3% 'Non-stent' patients (p¼0.003;
Figure 1).Characteristic % (Na)
History of smoking 84% (210/251)
Current diabetes mellitus 41% (104/251)
History of hyperlipidemia 75% (188/251)
History of hypertension 82% (205/251)
History of coronary artery disease 44% (110/251)
History of myocardial infarction 25% (63/251)
History of chronic heart failure 8% (21/251)
History of renal insufﬁciency 10% (24/251)
History of peripheral vascular surgery 10% (24/251)
History of other peripheral endovascular interventions 42% (106/251)
a8 patients did not have clinical history information available.
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dicants compared to a 'Non-stent' strategy for BTK interventions in CLI, with similar
need for RR and lower amputations in the 'Stent' group.
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Background: The ACHILLES study is a prospective, randomized, multi-center
comparison of balloon angioplasty and the Cypher SelectTM+ coronary and
infrapopliteal stent in the treatment of subjects with ischemic infrapopliteal arterial
disease. In total 200 subjects were included, according to a 1:1 randomization sche-
me. Patients were eligible for inclusion when presenting with clinical symptoms
according to Rutherford categories 3, 4 or 5 and presenting with de novo or restenosis
post-PTA lesions in the infrapopliteal vasculature. A maximum of 4 stents were
allowed to be implanted in maximally two lesions, with a lesion length of up to
90mm. Primary endpoint of ACHILLES is absence of in-segment binary restenosis
after 12 months, deﬁned as absence of binary restenosis (>50%) in and/or 5mm
proximal and/or 5mm distal to the treated segment as determined by quantita-
tive angiography (QA). Inclusion was ﬁnished in January 2010, no results are avail-
able yet.
Methods: Simultaneously, the 12-months results from another BTK-study, the
Drug Eluting Stents in the Critically Ischemic Lower Leg (DESTINY) study, are
being collected. This prospective, randomized, multi-center trial compares outcome
with the implant of the Abbott Vascular Xience V drug-eluting stent (DES) versus
the Abbott Vascular MultiLink Vision bare-metal stent (BMS) for treatment of
infrapopliteal arterial lesions of maximally 40mm long in patients with critical
limb ischemia (CLI). Patients eligible for inclusion had clinical symptoms
according to Rutherford categories 4 or 5 and presented with maximum of 2 below-
the-knee stenoses (50%) or occlusions is allowed, corresponding with a maximum
of 2 stents to be implanted. Primary endpoint of DESTINY is primary patency
after 12 months, deﬁned as 12-month angiographic binary in-stent restenosis
rate (>50% stenosis). Quantitative Vascular Analysis is performed, comparing
biplanar digital subtraction angiographic images immediately post-operatively and at
the 12 month follow-up control visit. Binary restenosis rate for DES and BMS at 12
months is compared using a Pearson Chi-square test, performed at the 5% signiﬁ-
cance level.
Results and Conclusions: Will be presented at TCT 2013.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-525
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Background: Lower limb ischemia due to atherosclerosis is associated with symp-
toms ranging from mild claudication to tissue loss. The purpose of the SuperNOVA
clinical study was to evaluate the safety and efﬁcacy of the investigational Innova
Self-Expanding Stent System (Boston Scientiﬁc Corporation, Natick, MA, USA) in
patients needing treatment of lesions in their femoropopliteal arteries.
Methods: The SuperNOVA study was a prospective, single arm, core lab-controlled,
multicenter, global clinical trial. Approximately 55 centers located in the United
States, Europe, Canada, and Japan enrolled up to 300 subjects. Eligibility for the study
included age >18 years with chronic lower limb ischemia deﬁned as Rutherford
categories 2, 3, or 4, and stenotic, restenotic (from angioplasty only), or occlusive
lesions located in the native superﬁcial femoral artery or proximal popliteal artery.
Target vessel diameter was 4 and 7 mm with stenosis at least 70% by visual
angiographic assessment, and total lesion length 30 mm and 190 mm. Following
device implantation, follow-up visits were scheduled at 1, 6, and 12 months. The
primary safety endpoint was occurrence of Major Adverse Events (i.e., all-cause death
through 1 month, target limb major amputation through 12 months, and target lesion
revascularization through 12 months). The primary efﬁcacy endpoint was vessel
primary patency at 12 months. Restenosis was deﬁned as duplex ultrasound systolic
velocity ratio >2.4.
Results: As of June 3, 2013, 259 patients were enrolled; 9.6% were 1 year post-
procedure. Mean age of the patients was 67.2 (SD 9.6) years and 74% were male; 82%
were Caucasian and 12% were Asian. Baseline clinical characteristics are shown in the
Table. Long stents (180-200 mm) were used by 40 patients.Conclusions: The SuperNOVA clinical investigation is ongoing. Enrollment is ex-
pected to be complete by June 2013.
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Background: Wound healing is very important endpoint in critical limb ischemia
(CLI) with tissue loss. The aim of this study was to design a scoring system for
predicting wound healing in CLI patients who were treated with endovascular therapy
(EVT) in consideration of various factors including patient background, intervention
outcomes, and also wound characteristics.
Methods: Between April 2007 and October 2012, 184 patients (217 limbs) were
treated with EVT for CLI with tissue loss in our institute. In these limbs, 236 indi-
vidual wounds existed and were divided into a development group (n¼118) and
a validation group (n¼118). Each variables which seem to be associated with wound
healing were analyzed using the univariate Cox proportional hazards model. All
variables tested in univariate analysis with p<0.25 were included in multivariate Cox
hazards model. The scores for each variables were transformed from regression
coefﬁcients and computed in a total score.acts/POSTER/Endovascular Intervention B159
